Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity

Area of Science:

• Immunology
• Immunotherapy
• T cell biology

Background:

• The OX40-OX40L axis is a key co-stimulatory pathway crucial for T cell responses.
• Preclinical studies demonstrate therapeutic efficacy for both activating (agonist) and blocking OX40-OX40L interactions.
• Unanswered questions remain regarding the precise immunomodulatory roles of OX40 across diverse T cell subsets.

Purpose of the Study:

• To review the impact of the OX40-OX40L interaction on various T cell subsets.
• To comprehensively understand anti-OX40 monoclonal antibody (mAb)-based therapies.
• To discuss the therapeutic applications of targeting the OX40-OX40L pathway in autoimmune diseases and cancer immunotherapy.

Main Methods:

• Literature review summarizing existing preclinical and clinical data.
• Analysis of the effects of OX40-OX40L modulation on T cell subsets including Th1, Th2, Th9, Th17, Th22, Treg, Tfh, and CD8+ T cells.
• Exploration of therapeutic strategies involving OX40 agonism and blockade.

Main Results:

• The OX40-OX40L interaction significantly influences the function of multiple T cell subsets.
• OX40-OX40L blockade may reduce immune activity and ameliorate T cell responses in autoimmune diseases.
• Agonist anti-OX40 mAbs activate T cells, enhancing anti-tumor activity, particularly when combined with other cancer therapies like checkpoint inhibitors.

Conclusions:

• Targeting the OX40-OX40L pathway holds significant therapeutic potential for T cell-mediated diseases.
• OX40-mediated therapies, especially agonist anti-OX40 mAbs in combination treatments, show promise for cancer immunotherapy.
• Further research into OX40's role in T cell subsets will refine anti-OX40 mAb-based therapeutic strategies.